Bank of Montreal Can Raises Stake in Amgen Inc. $AMGN

Key Points

• Bank of Montreal Can raised its Amgen stake 5.3% in Q3 to 1,063,079 shares (about 0.20% of the company), adding 53,566 shares and holding roughly $300 million worth of stock.
• The consensus analyst rating is a Hold with a $354 price target, amid mixed views (1 Strong Buy, 14 Buy, 13 Hold, 2 Sell) and notable price‑target increases from firms like Goldman Sachs ($415) and BMO Capital Markets ($372).
• Amgen recently beat quarterly expectations (EPS $5.29 vs. $4.76 est.; revenue $9.87B vs. $9.46B), set FY2026 guidance of 21.60–23.00 EPS, and declared a $2.52 quarterly dividend (annualized $10.08, ~2.7% yield).

Bank of Montreal Can increased its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 5.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,063,079 shares of the medical research company's stock after buying an additional 53,566 shares during the quarter. Bank of Montreal Can owned about 0.20% of Amgen worth $300,001,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the business. Evelyn Partners Investment Management LLP purchased a new position in shares of Amgen during the 2nd quarter valued at about $32,000. Howard Hughes Medical Institute purchased a new stake in Amgen in the 2nd quarter worth approximately $32,000. Cloud Capital Management LLC purchased a new stake in Amgen in the 3rd quarter worth approximately $34,000. AXS Investments LLC acquired a new stake in shares of Amgen during the 3rd quarter worth approximately $42,000. Finally, Winnow Wealth LLC purchased a new position in shares of Amgen during the 3rd quarter valued at approximately $47,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on AMGN shares. Jefferies Financial Group initiated coverage on shares of Amgen in a research note on Tuesday. They issued a "hold" rating and a $350.00 target price for the company. The Goldman Sachs Group raised their price target on shares of Amgen from $403.00 to $415.00 and gave the company a "buy" rating in a research report on Wednesday, February 4th. Truist Financial lifted their price objective on shares of Amgen from $318.00 to $319.00 and gave the company a "hold" rating in a report on Thursday, January 8th. BMO Capital Markets upped their price objective on shares of Amgen from $335.00 to $372.00 and gave the stock an "outperform" rating in a research report on Wednesday, December 3rd. Finally, Rothschild & Co Redburn increased their target price on shares of Amgen from $180.00 to $200.00 and gave the stock a "sell" rating in a research note on Wednesday, February 18th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have given a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $354.00.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Pipeline and capital returns: Coverage highlights Amgen’s oncology progress and frames the company’s dividend and buyback profile as supportive of long‑term growth and income, which underpins investor confidence in cash flow stability. Amgen Oncology Advances Test Dividend Strength And Long Term Growth Story
• Positive Sentiment: Industry endorsement: CNBC commentary cites Amgen as one of the larger biotech names that could be resilient amid structural changes (e.g., limited disruption from AI), which supports defensive large‑cap biotech demand. Biotech is resistant to AI disruption. Josh Brown likes these two stocks in the industry
• Positive Sentiment: Analyst/investor idea coverage: Earnings and strategy coverage from outlets like Zacks flag Amgen as a portfolio pick under their approach, reinforcing interest from strategy-driven investors. Take the Zacks Approach to Beat the Markets: Starbucks, Amgen, Allogene in Focus
• Neutral Sentiment: Short‑interest reporting appears anomalous: Data feeds show a reported increase in short interest but list zero shares/NaN values, suggesting the spike is likely a reporting glitch rather than confirmed bearish positioning. Monitor for corrected filings. (No direct article link—data entry reported.)
• Negative Sentiment: Analyst move: Jefferies initiated coverage on AMGN with a Hold rating and a $350 price target, signaling limited upside from current levels and contributing to downward pressure on the stock. Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence
• Negative Sentiment: Policy risk: A newly introduced bill (H.R. 7871) to codify Medicaid value‑based purchasing could change how discounts/rebates and outcomes‑based payments are calculated and reported. That framework may reduce realized prices or increase rebate liabilities for manufacturers that enter VBP arrangements—a potential long‑term headwind for Amgen’s pricing and margins in Medicaid. New Bill: Representative Brett Guthrie introduces H.R. 7871: Medicaid VBPs for Patients Act

Amgen Price Performance

Shares of NASDAQ AMGN opened at $375.43 on Wednesday. The firm has a market cap of $202.38 billion, a PE ratio of 26.38, a PEG ratio of 3.74 and a beta of 0.45. The firm has a fifty day moving average of $355.15 and a 200 day moving average of $323.95. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. Amgen Inc. has a one year low of $261.43 and a one year high of $391.29.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.76 by $0.53. The business had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company's revenue was up 8.6% compared to the same quarter last year. During the same period last year, the firm posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, research analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be issued a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.7%. The ex-dividend date is Friday, May 15th. Amgen's payout ratio is presently 70.84%.

About Amgen

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.